

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH **ATTENTION DEFICIT HYPERACTIVITY DISORDER**

1. AA Pharma Inc: **Desipramine**. *CA Product Monograph*. Vaughan, ON; 2012.
2. Amedra Pharmaceuticals LLC: **Dexedrine (dextroamphetamine)**. *US Product Monograph*. Horsham, PA; 2017.
3. Barrie ES, Pinsonneault JK, Sadee W, Hollway JA, Handen BL, Smith T, Arnold LE, Butter E, Hansen-Kiss E, Herman GE *et al*: **Testing genetic modifiers of behavior and response to atomoxetine in autism spectrum disorder with ADHD**. *J Dev Phys Disabil* 2018, **30**(3):355-371.
4. BC Renal Agency: **Antidepressant use in adults with chronic kidney disease**. 2015.
5. Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ, group SLIs: **Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD**. *CNS Spectr* 2005, **10**(12 Suppl 20):16-25.
6. Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L: **Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study**. *Pediatrics* 2005, **116**(6):e777-784.
7. Bjarnadottir GD, Johannsson M, Magnusson A, Rafnar BO, Sigurdsson E, Steingrimsson S, Asgrimsson V, Snorraddottir I, Bragadottir H, Haraldsson HM: **Methylphenidate disintegration from oral formulations for intravenous use by experienced substance users**. *Drug and alcohol dependence* 2017, **178**:165-169.
8. Boehringer Ingelheim Pharmaceuticals Inc: **Catapres (clonidine)**. *US Product Monograph*. Ridgefield, CT; 2016.
9. Boehringer Ingelheim Pharmaceuticals Inc: **Catapres TTS (clonidine patch)**. *US Product Monograph*. Ridgefield, CT; 2016.
10. Bolea-Alamanac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, Heal D, Muller U, Nash J, Santosh P *et al*: **Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology**. *Journal of psychopharmacology (Oxford, England)* 2014, **28**(3):179-203.
11. Brown JT, Abdel-Rahman SM, van Haandel L, Gaedigk A, Lin YS, Leeder JS: **Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD**. *Clinical pharmacology and therapeutics* 2016, **99**(6):642-650.

12. Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT *et al*: **Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy**. *Clinical pharmacology and therapeutics* 2019, **106**(1):94-102.
13. Byeon JY, Kim YH, Na HS, Jang JH, Kim SH, Lee YJ, Bae JW, Kim IS, Jang CG, Chung MW *et al*: **Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites**. *Archives of pharmacal research* 2015, **38**(11):2083-2091.
14. Canadian ADHD Resource Alliance (CADDRA): **Canadian ADHD practice guidelines**. Fourth Edition edn. Toronto, ON: CADDRA; 2018.
15. Canadian Pharmacists Association: **Tricyclic Antidepressants [CPhA Monograph]**. *RxTx*. Ottawa, ON; 2016.
16. Concordia Pharmaceuticals Inc: **Kapvay (clonidine ER)**. *US Product Monograph*. St. Michael, Barbados; 2018.
17. Connor DF, Fletcher KE, Swanson JM: **A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder**. *Journal of the American Academy of Child and Adolescent Psychiatry* 1999, **38**(12):1551-1559.
18. Cui YM, Teng CH, Pan AX, Yuen E, Yeo KP, Zhou Y, Zhao X, Long AJ, Bangs ME, Wise SD: **Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele**. *British journal of clinical pharmacology* 2007, **64**(4):445-449.
19. Cunill R, Castells X, Tobias A, Capella D: **Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression**. *Pharmacoepidemiol Drug Saf* 2013, **22**(9):961-969.
20. Donnelly M, Zametkin AJ, Rapoport JL, Ismond DR, Weingartner H, Lane E, Oliver J, Linnoila M, Potter WZ: **Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response**. *Clinical pharmacology and therapeutics* 1986, **39**(1):72-81.
21. **Pharmacogenomics guidelines** [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
22. Eli Lilly and Company: **Strattera (atomoxetine)**. *US Product Monograph*. Indianapolis, IN; 2018.
23. Eli Lilly Canada Inc: **Strattera (atomoxetine)**. *CA Product Monograph*. Toronto, ON; 2015.
24. Ermer J, Corcoran M, Lasseter K, Marbury T, Yan B, Martin PT: **A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of**

- Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.** *Therapeutic drug monitoring* 2016, **38**(4):546-555.
25. Feldman M, Belanger S: **Extended-release medications for children and adolescents with attention-deficit hyperactivity disorder.** *Paediatr Child Health* 2009, **14**(9):593-602.
 26. Fijal BA, Guo Y, Li SG, Ahl J, Goto T, Tanaka Y, Nisenbaum LK, Upadhyaya HP: **CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.** *Journal of clinical pharmacology* 2015, **55**(10):1167-1174.
 27. GlaxoSmithKline LLC: **Zyban (bupropion).** *US Product Monograph.* Research Triangle Park, NC; 2017.
 28. GlaxoSmithKline LLC: **Wellbutrin SR (bupropion).** *US Product Monograph.* Research Triangle Park, NC; 2017.
 29. Hamed M, Mohammadi M, Ghaleiha A, Keshavarzi Z, Jafarnia M, Keramatfar R, Alikhani R, Ehyaii A, Akhondzadeh S: **Bupropion in adults with Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind study.** *Acta medica Iranica* 2014, **52**(9):675-680.
 30. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A *et al*: **Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.** *Clinical pharmacology and therapeutics* 2017, **102**(1):37-44.
 31. Jain R, Segal S, Kollins SH, Khayrallah M: **Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.** *Journal of the American Academy of Child and Adolescent Psychiatry* 2011, **50**(2):171-179.
 32. Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V: **Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.** *European child & adolescent psychiatry* 2017, **26**(8):875-897.
 33. Kirch W, Kohler H, Braun W: **Elimination of guanfacine in patients with normal and impaired renal function.** *British journal of clinical pharmacology* 1980, **10 Suppl 1**:33s-35s.
 34. Kuperman S, Perry PJ, Gaffney GR, Lund BC, Bever-Stille KA, Arndt S, Holman TL, Moser DJ, Paulsen JS: **Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults.** *Ann Clin Psychiatry* 2001, **13**(3):129-134.

35. Lage M, Hwang P: **Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment.** *Journal of child and adolescent psychopharmacology* 2004, **14**(4):575-581.
36. Lexicomp: **Dextroamphetamine and amphetamine.** *LexiDrugs.* Hudson, Ohio: Wolters Kluwer Health; 2018.
37. Lexicomp: **Guanfacine.** *Lexi-Drugs.* Hudson, Ohio: Wolters Kluwer Health; 2018.
38. Lilly USA LLC: **Strattera (atomoxetine).** In: *US Product Monograph.* Indianapolis, IN; 2017.
39. Loghin C, Haber H, Beasley CM, Jr., Kothare PA, Kauffman L, April J, Jin L, Allen AJ, Mitchell MI: **Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers.** *British journal of clinical pharmacology* 2013, **75**(2):538-549.
40. Marcus SC, Wan GJ, Kemner JE, Olfson M: **Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.** *Arch Pediatr Adolesc Med* 2005, **159**(6):572-578.
41. Matsui A, Azuma J, Witcher JW, Long AJ, Sauer JM, Smith BP, DeSante KA, Read HA, Takahashi M, Nakano M: **Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men.** *Journal of clinical pharmacology* 2012, **52**(3):388-403.
42. McCormack J, Carleton B, Calissi P: **Dosage Adjustment in Renal Impairment.** *Therapeutics.* Ottawa, ON: Canadian Pharmacists Association; 2015.
43. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J: **CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.** *Journal of the American Academy of Child and Adolescent Psychiatry* 2007, **46**(2):242-251.
44. Mint Pharmaceuticals Inc: **Mint-Clonidine (clonidine hydrochloride).** *CA Product Monograph.* Mississauga, ON; 2017.
45. National Institute for Health and Care Excellence: **Attention deficit hyperactivity disorder: diagnosis and management. [NICE Guideline NG87].** 2018.
46. Novartis Pharmaceuticals Canada Inc: **Ritalin (methylphenidate hydrochloride).** *CA Product Monograph.* Dorval, QC; 2017.
47. Novartis Pharmaceuticals Corporation: **Ritalin (methylphenidate hydrochloride) US Product Monograph.** East Hanover, NJ; 2019.
48. Paladin Labs Inc: **Dexedrine (dextroamphetamine).** *CA Product Monograph.* St-Laurent, QC; 2016.

49. Palumbo DR, Sallee FR, Pelham WE, Jr., Bukstein OG, Daviss WB, McDermott MP: **Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes.** *Journal of the American Academy of Child and Adolescent Psychiatry* 2008, **47**(2):180-188.
50. Parasrampur DA, Schoedel KA, Schuller R, Silber SA, Ciccone PE, Gu J, Sellers EM: **Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.** *Journal of clinical psychopharmacology* 2007, **27**(5):459-467.
51. Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z: **A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder.** *The Australian and New Zealand journal of psychiatry* 1999, **33**(4):494-502.
52. Poulin C: **From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots.** *Addiction* 2007, **102**(5):740-751.
53. Purdue Pharma: **Biphentin (methylphenidate).** *CA Product Monograph.* Pickering, ON; 2017.
54. Purdue Pharma: **Foquest (methylphenidate).** *CA Product Monograph.* Pickering, ON; 2017.
55. Ramos N, Boni C, Downing AM, Close SL, Peters SL, Prokop AM, Allen AJ, Hamon M, Purper-Ouakil D, Gorwood P: **A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).** *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2009, **34**(9):2135-2142.
56. Reimherr FW, Hedges DW, Strong RE, Marchant BK, Williams ED: **Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial.** *Neuropsychiatric Disease and Treatment* 2005, **1**(3):245-251.
57. Rhodes Pharmaceuticals LP: **Aptensio XR (methylphenidate).** *US Product Monograph.* Coventry, RI; 2015.
58. Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP: **Assessment of adherence measures with different stimulants among children and adolescents.** *Pharmacotherapy* 2005, **25**(7):909-917.
59. Sanis Health Inc: **Bupropion SR.** In: *CA Product Monograph.* Brampton, ON; 2017.
60. sanofi-aventis US LLC: **Norpramin (desipramine).** *US Product Monograph.* Bridgewater, NJ 2014.

61. Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, Desante KA: **Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.** *Drug metabolism and disposition: the biological fate of chemicals* 2003, **31**(1):98-107.
62. Shire LLC: **Vyvanse (lisdexamfetamine).** *US Product Monograph.* Lexington, MA; 2018.
63. Shire Pharma Canada ULC: **Adderall XR (mixed salts amphetamine) CA Product Monograph.** Saint-Laurent, QC; 2015.
64. Shire Pharma Canada ULC: **Vyvanse (lisdexamfetamine).** *CA Product Monograph.* Saint-Laurent, QC; 2016.
65. Shire Pharma Canada ULC: **Intuniv XR (guanfacine hydrochloride).** *CA Product Monograph.* Toronto, ON; 2017.
66. Shire US Manufacturing Inc: **Adderall XR (mixed salts of a single-entity amphetamine product)** *US Product Monograph.* Lexington, MA; 2018.
67. Shire US Manufacturing Inc: **Intuniv (guanfacine).** *US Product Monograph.* Lexington, MA; 2018.
68. Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR: **Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.** *Journal of child and adolescent psychopharmacology* 2009, **19**(5):501-510.
69. Spiller HA, Hays HL, Aleguas A: **Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.** *CNS drugs* 2013, **27**(7):531-543.
70. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE: **A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.** *Can J Clin Pharmacol* 2006, **13**(1):e50-62.
71. Subcommittee on Attention-Deficit/Hyperactivity Disorder Steering Committee on Quality Improvement Management, Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B *et al*: **ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.** *Pediatrics* 2011, **128**(5):1007-1022.
72. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines.** *Clinical pharmacology and therapeutics* 2011, **89**(5):662-673.

73. Teva Canada Limited: **Alertec (modafinil)**. *CA Product Monograph*. Toronto, ON; 2017.
74. Teva Pharmaceuticals USA Inc: **Provigil (modafinil)** *US Product Monograph*. North Wales, PA; 2015.
75. Trzepacz PT, Williams DW, Feldman PD, Wrishko RE, Witcher JW, Buitelaar JK: **CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD**. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* 2008, **18**(2):79-86.
76. University of Michigan Health System: **For Health Professionals: Clinical Practice Guidelines: ADHD**. 2013.
77. Valeant Canada LP: **Zyban (bupropion)**. *CA Product Monograph*. Laval, QC; 2016.
78. Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK, Read SC, Tulloch SJ: **Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial**. *CNS Spectr* 2006, **11**(8):625-639.
79. Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, Schleifer D, Harding M, Linehan C, Geller D: **Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder**. *The American journal of psychiatry* 1996, **153**(9):1147-1153.
80. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, Polisner D, Solhkhah R, Comeau S, Monuteaux MC *et al*: **A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults**. *The American journal of psychiatry* 2001, **158**(2):282-288.
81. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J: **Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications**. *Journal of the American Academy of Child and Adolescent Psychiatry* 2006, **45**(4):408-414.
82. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S: **Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature**. *Journal of the American Academy of Child and Adolescent Psychiatry* 2008, **47**(1):21-31.
83. Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulos A, Doyle RL, Martelon M, Brodziak K: **An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness**. *Journal of child and adolescent psychopharmacology* 2009, **19**(5):485-492.